10. Metzger NL, Chesson MM. Subcutaneous Unfractionated Heparin for Treatment of Venous Thromboembolism in End-Stage Renal Disease.
|
|
|
- Grant Powers
- 7 years ago
- Views:
Transcription
1 DAFTAR PUSTAKA 1. Cade JF.High risk of the critically ill for venous thromboembolism.crit Care Med 1982;10: Belch J J, Lowe GD, Ward AG, et al. Prevention of deep veinthrombosis in medical patients by low-dose heparin. ScottMedJ 1981;26: Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deepvenous thrombosis among patients in medical intensivecare.jama 1995;274: Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. SeminThrombHemost 2002, 28(Suppl 2): Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: the eight american college of chest physicians evidence-based clinical practice guidelines. Chest 2008;133;381S-453S. 6. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease* :american college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133; 454S-545S 7. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants* :american college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133;141S-159S 8. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecularweight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009;43: Levey SA, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:
2 10. Metzger NL, Chesson MM. Subcutaneous Unfractionated Heparin for Treatment of Venous Thromboembolism in End-Stage Renal Disease. Ann Pharmacother 2010;44: Bentley PG, Kakkar VV, Scully MF, MacGregor IR, Webb P, Chan P, Jones N. An objective study of alternative methods of heparin administration.thrombosis Research 1980;18; Andersson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg B, Nilsson E, Wilhelmsson S, ZetterquistS.Subcutaneous Administration of heparin: a randomized comparison with intravenous administration of heparin to patients with deep-vein thrombosis. Thrombosis Research 1982;27; Robinson AM, McLean KA, Greaves M, Channer KS. Subcutaneous versus intravenous administration of heparin in the treatment of deep vein thrombosis; which do patients prefer? a randomized cross-over study. Postgrad Med J 1993;69: Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med 1992;116: Sukrisman, Lugyanti. Trombosis Vena Dalam dan Emboli Paru. In: Sudoyo Aru W, et. al (eds.)buku Ajar Ilmu Penyakit Dalam. 2nd ed. Jakarta Pusat: Fakultas Kedokteran Universitas Indonesia; p Venous Thrombosis: The Role of Genes, Environment, dan Behavior, ASH Education Book January 1, 2005 vol no Andrews KL, Gamble GL, et al. Vascular Diseases. In: Delisa JA, editor. PhysicalMedicine & Rehabilitation Principles and Practice, 4th Edition. Phyladelphia: LippincottWilliams & Wilkins; p Heit JA, Silverstein MD. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med (Mar 27); 160(6): Deep vein thrombosis. National Heart, Lung, and Blood Institute. Accessed May 29, 2011.
3 20. Fauci et al., editor. Venous Thrombosis. In: Harrison Principles of Internal Medicine. 17 th ed. USA:The McGraw-Hill Companies; Kessler C.M. The link between cancer and venous Thromboembolism: A review. Am J Clin Oncol. 2009;32: S3-S Bombeli T, Spahn D.R. Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage. Br J Anaesthesia, 2004; 93: M, Nelson, D. Lehninger, Principles of Biochemistry. Freeman; p Katzung, Bertram G Farmakologi Dasar dan Klinik. Jakarta: EGC. 33: Nader, HB et al. Heparan sulfates and heparins: similar compounds performing the same functions in vertebrates and invertebrates. Brazilian Journal Medical iology Research. 1999; 32 (5): Mary J. Mycek et al. Farmakologi Ulasan Bergambar. Edisi2. Jakarta: Widya Medika. 2001; 20: Dewoto, R. Hedi Antikoagulan, Antitrombotik, Trombolitik, dan Hemostatik. Jakarta: Fakultas Kedokteran UI; 51: Gupta S, Bhagotra A, Gulati S, Sharma J. Guidelines for the transport of critically ill patients: clinical guide.jk Science2004; Vol. 6 No. 2: Hall, Guyton Buku Ajar Fisiologi Kedokteran. Jakarta: ECG; 36: Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 2009; 114:759
4 LAMPIRAN Lampiran 1. Hasil Output SPSS a) Uji Normalitas Tests of Normality Kolmogorov-Smirnov a Shapiro-Wilk Statistic df Sig. Statistic df Sig * * * *. This is a lower bound of the true significance. a. Lilliefors Significance Correction b) Deskriptif, 2, 3 300, , ,000 0
5 Descriptives Mean Interval for Mean Lower Bound Upper Bound Statistic Std. Error % Trimmed Mean Median Variance Std. Deviation Minimum Maximum Range Interquartile Range Skewness Kurtosis Mean Interval for Mean Lower Bound Upper Bound E % Trimmed Mean Median Variance Std. Deviation Minimum Maximum Range Interquartile Range Skewness Kurtosis Mean Interval for Mean Lower Bound Upper Bound E % Trimmed Mean Median Variance Std. Deviation Minimum Maximum Range Interquartile Range Skewness Kurtosis E
6 c). T-Test ed Samples Statistics Std. Error Mean N Std. Deviation Mean ed Samples Correlations & & & N Correlation Sig ed Samples Test ed Differences Interval of the Std. Std. Error Difference Sig. Mean Deviation Mean Lower Upper t df (2-tailed) d) Deskripsi selisih jumlah trombosit Descriptive Statistics Selisih - 2 Selisih - 3 Selisih - 3 Valid N (listwise) N Minimum Maximum Mean Std. Deviation
7 Lampiran 4. Biodata mahasiswa Identitas Nama NIM : Wimardy Leonard Wijaya : G2A Tempat/tanggal lahir : Bengkulu, 18 Agustus 1991 Jenis kelamin Alamat : Laki-laki : Jalan Asem 1 79A Duri Kepa Jakarta Barat Nomor Telepon : wimardy.leonard@gmail.com Riwayat Pendidikan Formal 1. SD St. Carolus Bengkulu ( ) 2. SMP St Carolus Bengkulu ( ) 3. SMA Kolese Kanisius Jakarta ( ) 4. Fakultas Kedokteran Universitas Diponegoro ( sekarang) Keanggotaan Organisasi 1. Wakil ketua PRMK FK UNDIP ( )
Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
Backgrounder. Current anticoagulant therapies
Backgrounder Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Current anticoagulant therapies Anticoagulant drugs have significantly reduced the risk of thromboembolic events
Prior Authorization Guideline
Guideline Guideline Name Formulary Xarelto (rivaroxaban) UnitedHealthcare Community & State Approval Date 0/0/203 Revision Date 8//204 Technician Note: CPS Approval Date: /5/20; CPS Revision Date: 8/20/204
13. Porter ML, Dennis BL. Hyperbilirubinemia in the term newborn. Am Fam Physician. 2002;65:599-606.
DAFTAR PUSTAKA 1. Dewiyana. PONED sebagai strategi untuk persalinan yang aman. Litbangkes dinas kesehatan provinsi Jawa Timur; 2010. Available from: URL: http://dinkes.jatimprov.go.id/userimage/subdin/poned%20sebagai%20strat
Pharmacological prophylaxis for venous thromboembolism
Pharmacological prophylaxis for venous thromboembolism Essence of this ArticleFor more than 20 years, routine preventive anticoagulant therapy has been the standard of care after major orthopaedic surgery.
DVT and Pulmonary Embolism: Part II. Treatment and Prevention
PRACTICAL THERAPEUTICS DVT and Pulmonary Embolism: Part II. Treatment and Prevention DINO W. RAMZI, M.D., C.M., and KENNETH V. LEEPER, M.D. Emory University School of Medicine, Atlanta, Georgia Treatment
New Oral Anticoagulants: Topic Brief
New Oral Anticoagulants: Topic Brief June 9, 2015 High-Level Research Question In patients with nonvalvular atrial fibrillation (AF) or venous thromboembolic disease, or who have undergone surgery for
Chapter 2 Probability Topics SPSS T tests
Chapter 2 Probability Topics SPSS T tests Data file used: gss.sav In the lecture about chapter 2, only the One-Sample T test has been explained. In this handout, we also give the SPSS methods to perform
ACCP MODEL PRACTICE. A Pharmacist-Staffed Inpatient Antithrombosis Service. American College of Clinical Pharmacy. William E. Dager, Pharm.D.
ACCP MODEL PRACTICE A Pharmacist-Staffed Inpatient Antithrombosis Service American College of Clinical Pharmacy William E. Dager, Pharm.D. a a Pharmacist Specialist, University of California Davis Medical
XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery
XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery Fast Facts: XARELTO is a novel, once-daily, oral anticoagulant recently approved in the United States for the prevention (prophylaxis)
Treatment of Venous Thromboembolism in Cancer Patients
The role of low-molecular-weight heparin in cancer patients with acute venous thromboembolism and how it improves outcomes are discussed. Jacky Tiplady. Jersey Cottages. Photograph. Treatment of Venous
Independent t- Test (Comparing Two Means)
Independent t- Test (Comparing Two Means) The objectives of this lesson are to learn: the definition/purpose of independent t-test when to use the independent t-test the use of SPSS to complete an independent
Chapter 2 Incidence of Venous Thromboembolism in Orthopedic Surgery
Chapter 2 Incidence of Venous Thromboembolism in Orthopedic Surgery Ajay K. Kakkar and Sophie K. Rushton-Smith Abstract Venous thromboembolic disease in hospitalized patients results in substantial mortality,
A Prospective, Controlled Trial of a Pharmacy-Driven Alert System to Increase. Thromboprophylaxis Rates in Medical Inpatients
1 A Prospective, Controlled Trial of a Pharmacy-Driven Alert System to Increase Thromboprophylaxis Rates in Medical Inpatients David A. Garcia, MD, Jessica Highfill, Katie Finnerty, Keith Hutchinson, MD
DATE: 06 May 2013 CONTEXT AND POLICY ISSUES
TITLE: Low Molecular Weight Heparins versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness DATE: 06
Pharmacoeconomic implications of thromboprophylaxis with new oral anticoagulants
Pharmacoeconomic implications of thromboprophylaxis with new oral anticoagulants after total hip or knee replacement in the United States Submitted to: Expert Opin Pharmacother Running head: Pharmacoeconomic
ECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding
To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
DEEP VEIN THROMBOSIS: TREATMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
DVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery
Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery Position Statement There is currently insufficient data for the (AOFAS) to recommend for or against routine VTED prophylaxis for
Knee Replacement Surgery and Blood Clots What You Need To Know
Knee Replacement Surgery and Blood Clots What You Need To Know This leaflet was developed and funded by the Pfizer/BMS Alliance in partnership with Anticoagulation Europe. This leaflet is intended for
The novel anticoagulants: entering a new era
Review article Peer reviewed article SWISS MED WKLY 2009;139(5 6):60 64 www.smw.ch 60 The novel anticoagulants: entering a new era Henri Bounameaux Division of Angiology and Haemostasis, Department of
To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients.
UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To aid practitioners in prescribing unfractionated heparin and low-molecular-weight
CHEST Antithrombotic Therapy and Prevention of Thrombosis, 9 th ed Sarah Meyer, PharmD November 9, 2012
CHEST Antithrombotic Therapy and Prevention of Thrombosis, 9 th ed Sarah Meyer, PharmD November 9, 2012 1. CHEST has made a few changes 1 a. For patients sufficiently healthy to be treated as outpatients,
Confirmed Deep Vein Thrombosis (DVT)
Confirmed Deep Vein Thrombosis (DVT) Information for patients What is deep vein thrombosis? Blood clotting provides us with essential protection against severe loss of blood from an injury to a vein or
The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?
AACE 23 rd Annual Scientific and Clinical Congress (2014) Syllabus Materials: The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? JoAnn E. Manson, MD, DrPH, FACP, FACE Chief, Division
MAKING CARE SAFER FROM HOSPITAL TO HOME CARE. A collaborative report from Accreditation Canada and the Canadian Patient Safety Institute
MAKING CARE SAFER FROM HOSPITAL TO HOME CARE A collaborative report from Accreditation Canada and the Canadian Patient Safety Institute 2014 Canadian Patient Safety Institute and Accreditation Canada All
ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014
ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014 Thromboembolism epidemiology 5 million DVT s 900,000 PE s 290,000 fatalities Heit J. Blood. 2005;106:910. 10 VTE events Since this talk began DVT
Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2
Bleeding/Clotting Risk Evaluation Tools for Atrial Fibrillation Patients Before prescribing anticoagulants, providers should weigh the risk of thrombosis against the risk of bleeding. The tools below can
The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
I know my value. Be an active part of your anticoagulation therapy with INR self-monitoring
I know my value Be an active part of your anticoagulation therapy with INR self-monitoring INR* self-monitoring needs only a drop of blood, is easy, fast and decreases the possibility Be involved in your
UNDERSTANDING THE INDEPENDENT-SAMPLES t TEST
UNDERSTANDING The independent-samples t test evaluates the difference between the means of two independent or unrelated groups. That is, we evaluate whether the means for two independent groups are significantly
Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism
Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism NATHAN T. CONNELL, MD, MPH; JAMES N. BUTERA, MD ABSTRACT Until recently, warfarin has been
Outpatient strategies in the management of deep
PRIMER: THE LOVELACE OUTPATIENT TREATMENT PROGRAM Alex C. Spyropoulos, MD Outpatient strategies in the management of deep venous thrombosis (DVT) are gaining acceptance in U.S. health care centers. Observational
DISCLAIMER ARTHROPLASTY SOCIETY VTE INFORMATION
DISCLAIMER ARTHROPLASTY SOCIETY VTE INFORMATION Venous thromboembolism is the most common complication after total hip and total knee arthroplasty. In recent times members of the Australian Orthopaedic
3rd. VTE 7 (Venous Thromboembolism) most common cardiovascular condition worldwide 1. Most common avoidable cause of hospital death 2
most common cardiovascular condition worldwide 1 3rd VTE (Venous thromboembolism) Thromboembolism) 7 (Venous Thromboembolism) Most common avoidable cause of hospital death 2 EVERY Deep vein thrombosis
Eliquis. Policy. covered: Eliquis is. indicated to. reduce the. therapy. Eliquis is. superior to. of 32 to. Eliquis is AMPLIFY. nonfatal. physicians.
Eliquis (apixaban) Policy Number: 5.01.573 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Eliquis when it is determined to be medically necessary
Published 2011 by the American Academy of Orthopaedic Surgeons 6300 North River Road Rosemont, IL 60018. AAOS Clinical Practice Guidelines Unit
Volume 4. AAOS Clinical Guideline on Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty Comparison with Other Guidelines Disclaimer This clinical guideline
DEEP VENOUS THROMBOSIS PROPHYLAXIS IN SURGICAL PATIENTS
DISCLAIMER: These guidelines were prepared jointly by the Surgical Critical Care and Medical Critical Care Services at Orlando Regional Medical Center. They are intended to serve as a general statement
Two Related Samples t Test
Two Related Samples t Test In this example 1 students saw five pictures of attractive people and five pictures of unattractive people. For each picture, the students rated the friendliness of the person
Antithrombotic therapy
Orthogeriatrics Clinical Summary Document Antithrombotic therapy Topics Preexisting anticoagulation and timing of surgery Reversal of anticoagulation Perioperative thromboprophylaxis When should we be
National Patient Safety Goals Effective January 1, 2015
National Patient Safety Goals Goal 1 Nursing are enter ccreditation Program Improve the accuracy of patient and resident identification. NPSG.01.01.01 Use at least two patient or resident identifiers when
Thrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC
To Bridge or Not to Bridge Periop Anticoagulation Management Don Weinshenker, MD Ambulatory Care Denver VAMC Financial Disclosure Information Nothing to report Periop AC Management Chronically anti-coagulated
Direct Oral Anticoagulants for Acute Venous Thromboembolism: Closing the Circle?
Direct Oral Anticoagulants for Acute Venous Thromboembolism: Closing the Circle? Running title: Verhamme et al.; DOACs for acute venous thromboembolism Peter Verhamme, MD, PhD 1 ; Henri Bounameaux, MD
STROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
The Global Alliance against Chronic Respiratory Diseases
The Global Alliance against Chronic Respiratory Diseases Pulmonary hypertension Dr Marc Humbert What is the burden of pulmonary hypertension? The true burden of pulmonary hypertension is currently unknown
PROTOCOL TITLE: Ambulatory Initiation and Management of Warfarin for Adults
PROTOCOL NUMBER: 7 PROTOCOL TITLE: Ambulatory Initiation and Management of Warfarin for Adults THIS PROTOCOL APPLIES TO: UW Health Clinics: all adult outpatients with an active order for warfarin TARGET
Antithrombotic Therapy for VTE Disease
CHEST Supplement ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
Friday April 8 th 2016
Preliminary Scientific Program - ICTHIC April 8-10, 2016 Friday April 8 th 2016 9,00-11,00 am Industry sponsored session 11,00-11,15 am Congress Opening: A Falanga, FR Rickles, B Brenner 11,15-1,30 pm
How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto
News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval
CLINICAL PRACTICE GUIDELINE: MOBILITY WITH A DEEP VEIN THROMBOSIS (DVT) Page 1 of 10
Page 1 of 10 1.0 FOCUS: Mobilization with a Deep Vein Thrombosis (DVT). The purpose of this clinical practice guideline (CPG) is to ensure that new knowledge is integrated across Fraser Health and to standardize
ABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
Antithrombotic Therapy for VTE Disease
CHEST Supplement ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
National Patient Safety Goals Effective January 1, 2015
National Patient Safety Goals Effective January 1, 2015 Goal 1 Improve the accuracy of resident identification. NPSG.01.01.01 Long Term are ccreditation Program Medicare/Medicaid ertification-based Option
Randomized, double-blind, parallel-group, multicenter, doubledummy
ABOUT RECORD STUDIES FAST FACTS RECORD is a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism (VTE)
Oral Anticoaginal Therapy (VTE) and Its Effect on Recurrence
VOLUME 45ㆍ NUMBER 1ㆍ MARCH 2010 THE KOREAN JOURNAL OF HEMATOLOGY REVIEW ARTICLE Recent advances in the management of venous thromboembolism Walter Ageno Research Center on Thromboembolic Diseases and Antithrombotic
INTERPRETING THE ONE-WAY ANALYSIS OF VARIANCE (ANOVA)
INTERPRETING THE ONE-WAY ANALYSIS OF VARIANCE (ANOVA) As with other parametric statistics, we begin the one-way ANOVA with a test of the underlying assumptions. Our first assumption is the assumption of
Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital
Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital Jonathan Sykes MD, CMIO Jacalyn Liebowitz RN, MBA,NEA-BCFACHE VP Care Continuum Allegiance Health - Jackson, MI DISCLAIMER:
Value-Based Purchasing
Emerging Topics in Healthcare Reform Value-Based Purchasing Janssen Pharmaceuticals, Inc. Value-Based Purchasing The Patient Protection and Affordable Care Act (ACA) established the Hospital Value-Based
STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
Limitations of VKA Therapy
Fibrillazione Atriale Non Valvolare Ischemia o Emorragia le Due Utopie Rivali nella Scelta dei NAO Gianluca Botto, MD, FESC, UO Elettrofisiologia, Dip Medicina Limitations of VKA Therapy Unpredictable
Objectives. Oral Anticoagulants. Assessment Question No. 1. FDA Approved Indications. Warfarin
Assessment of Target Specific Oral Anticoagulant Prescribing Rationale and Adverse Event Pilot Comparison in Veterans Receiving Oral Anticoagulation Therapy Angela Mechelay, Pharm.D. PGY1 Pharmacy Resident
Pulmonary Embolism Treatment Update
UC SF Pulmonary Embolism Treatment Update Jeffrey Tabas, MD Professor UCSF School of Medicine Emergency Department San Francisco General Hospital sf g h Disclosure No Financial Relationships to Disclose
Your Guide to Preventing and Treating Blood Clots
Your Guide to Preventing and Treating Blood Clots U.S. Department of Health and Human Services Agency for Healthcare Research and Quality 540 Gaither Road Rockville, MD 20850 AHRQ Pub. No. 09 0067 C May
Test Content Outline Effective Date: February 6, 2015. Cardiac-Vascular Nursing Board Certification Examination
Effective Date: February 6, 2015 Board Certification Examination There are 175 questions on this examination. Of these, 150 are scored questions and 25 are pretest questions that are not scored. Pretest
Information for you Treatment of venous thrombosis in pregnancy and after birth. What are the symptoms of a DVT during pregnancy?
Information for you Treatment of venous thrombosis in pregnancy and after birth Published in September 2011 What is venous thrombosis? Thrombosis is a blood clot in a blood vessel (a vein or an artery).
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
original article Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients Alexander T. Cohen, M.D., Theodore E. Spiro, M.D., Harry R. Büller, M.D., Lloyd Haskell, M.D., Dayi Hu, M.D., Russell
Executive Summary. Motive for the request for advice
Executive Summary Motive for the request for advice Currently nearly 400,000 people in the Netherlands are being treated with anticoagulants of a type Vitamin K antagonists (VKAs). Although VKAs are very
Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
Elevated Serum Lactate Dehydrogenase Values in Children with Multiorgan Involvements and Severe Febrile Illness
Iranian Journal of Pediatrics Society Volume 1, Number 1, 2007: 31-35 Original Article Elevated Serum Lactate Dehydrogenase Values in Children with Multiorgan Involvements and Severe Febrile Illness Farah
Practice Pearls in the Changing Face of Anticoagulant Therapy
Practice Pearls in the Changing Face of Anticoagulant Therapy A midday symposium about the use of anticoagulation to prevent venous thromboembolism (VTE) was held at and broadcast live from the 44th ASHP
Disclosures. Objective (NRHS) Self Assessment #2
Development and Implementation of a Protocol for Reversing the Effects of Anticoagulants for Use in a Community Hospital Samantha Sepulveda, Pharm.D. PGY1 Pharmacy Resident Norman Regional Health System
Recently, a pediatric physical therapy manager. Early Ambulation After Acute Deep Vein Thrombosis: Is It Safe? Marilyn Slavin Blumenstein, MSN, RN
Early Ambulation After Acute Deep Vein Thrombosis: Is It Safe? Marilyn Slavin Blumenstein, MSN, RN The number of thrombotic events in children, although significantly less than that in adults, is increasing
ORIGINAL CLINICAL INVESTIGATION
Prins et al. Thrombosis Journal 2013, 11:21 ORIGINAL CLINICAL INVESTIGATION Open Access Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis
What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?
Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning A Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning Drugs to Prevent Abnormal Blood
Key words: deep venous thrombosis; low-molecular-weight heparin; orthopedic surgery; thromboprophylaxis; venous thromboembolism
Identifying Orthopedic Patients at High Risk for Venous Thromboembolism Despite Thromboprophylaxis* Renée L. Schiff, MD; Susan R. Kahn, MD, MSc; Ian Shrier, MD, PhD; Carla Strulovitch, RN; Wahbi Hammouda,
ORIGINAL CLINICAL INVESTIGATION
Ageno et al. Thrombosis Journal 2014, 12:16 ORIGINAL CLINICAL INVESTIGATION Open Access ALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial
Venous Thromboembolic Treatment Guidelines
Venous Thromboembolic Treatment Guidelines About the NYU Venous Thromboembolic Center (VTEC) The center s mission is to deliver advanced screening, detection, care, and management services for patients
Venous Thromboembolism
PREVENTION OF Venous Thromboembolism The Australia & New Zealand Working Party on the Management and Prevention of Venous Thromboembolism. Best Practice Guidelines for Australia & New Zealand 4th Edition
Cancer and the Heparins
WP Ceelen, MD, PhD Department of GI Surgery - UZ Gent Senior Clinical Researcher - FWO Overview Mechanisms of cancer induced thrombosis Guidelines for prevention and treatment of VTE in cancer patients
Clive Kearon, Susan R. Kahn, Giancarlo Agnelli, Samuel Goldhaber, Gary E. Raskob and Anthony J. Comerota. DOI 10.1378/chest.
Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Clive Kearon, Susan R. Kahn, Giancarlo Agnelli,
Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry
Journal of Thrombosis and Haemostasis, 10: 2045 2052 DOI: 10.1111/j.1538-7836.2012.04877.x ORIGINAL ARTICLE Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery:
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
September 12, 2011. Dear Dr. Corrigan:
September 12, 2011 Janet M. Corrigan, PhD, MBA President and Chief Executive Officer National Quality Forum 601 13th Street, NW Suite 500 North Washington, D.C. 20005 Re: Measure Applications Partnership
British Journal of Anaesthesia 101 (2): 250 4 (2008) doi:10.1093/bja/aen132 Advance Access publication May 30, 2008
British Journal of Anaesthesia 11 (2): 25 4 (28) doi:1.193/bja/aen132 Advance Access publication May 3, 28 REGIONAL ANAESTHESIA International normalized ratio and prothrombin time values before the removal
This supplement contains the following items:
This supplement contains the following items: 1. Original protocol (the version of the protocol is unique because it has not been changed). 2. Original statistical analysis plan, final statistical analysis
Preventing Blood Clots in Adult Patients. Information For Patients
Preventing Blood Clots in Adult Patients Information For Patients 1 This leaflet will give you information on how to reduce the risk of developing blood clots during and after your stay in hospital. If
Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016
Cost-Saving Approach to Patients on Long-Term Anticoagulation Who Need Endoscopy: A Decision Analysis
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 98, No. 8, 2003 2003 by Am. Coll. of Gastroenterology ISSN 0002-9270/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0002-9270(03)00445-3 Cost-Saving Approach
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
Information resources for patients and carers. Anticoagulation. Anticoagulation in pregnancy. Anticoagulation in increased bleeding risk cases
Background information Information resources for patients and carers Updates to this pathway Anticoagulation Contraindications to anticoagulation Anticoagulation in increased bleeding risk cases Anticoagulation
Paul G. Lee. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume III, 1998-1999. A. Objective
A comparison of six months of anticoagulation with extended anticoagulation for a first episode of venous thromboembolism in patients with thrombophilia Paul G. Lee A. Objective a. To evaluate the risk
Rivaroxaban, an Oral, Direct Factor Xa Inhibitor: A New Option for Thromboprophylaxis
n Feature Article, an Oral, Direct Factor Xa Inhibitor: A New Option for Thromboprophylaxis Louis M. Kwong, MD, FACS abstract Full article available online at Healio.com/Orthopedics. Search: 20120525-38